Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

NCT02684292 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

BIOLOGICAL: pembrolizumab
BIOLOGICAL: brentuximab vedotin

Sponsor

Merck Sharp & Dohme LLC